Vorinostat Completed Phase 2 Trials for Sickle Cell Disorders Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01000155Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease